Hypera S.A. (OTCMKTS:HYPMY – Get Free Report) reached a new 52-week low during mid-day trading on Thursday . The company traded as low as $4.60 and last traded at $4.71, with a volume of 53475 shares traded. The stock had previously closed at $4.78.
Hypera Price Performance
The firm’s fifty day moving average is $5.16 and its 200 day moving average is $5.40. The firm has a market capitalization of $2.98 billion, a price-to-earnings ratio of 8.97 and a beta of 1.04.
Hypera (OTCMKTS:HYPMY – Get Free Report) last released its quarterly earnings data on Thursday, July 25th. The company reported $0.15 earnings per share (EPS) for the quarter. The firm had revenue of $420.00 million for the quarter.
Hypera Company Profile
Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.
See Also
- Five stocks we like better than Hypera
- What Investors Need to Know About Upcoming IPOs
- Taiwan Semiconductor Soars on Earnings With More Room to Run
- How to Find Undervalued Stocks
- Is Lucid Group Nearing the Bottom? What Investors Should Know
- Find and Profitably Trade Stocks at 52-Week Lows
- 90% Gain Possible? Analysts Are Bullish on Joby Aviation
Receive News & Ratings for Hypera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hypera and related companies with MarketBeat.com's FREE daily email newsletter.
